推荐产品
等級
pharmaceutical primary standard
API 家族
enalapril
製造商／商標名
USP
應用
pharmaceutical (small molecule)
格式
neat
SMILES 字串
C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O
InChI
1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1
InChI 密鑰
UQKQUZOIQFOJOI-KJHLASMFSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Enalapril maleate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Enalapril Maleate Tablets
- Enalapril Maleate and Hydrochlorothiazide Tablets
- Enalapril Maleate Compounded Oral Suspension
- Enalaprilat Injection
生化／生理作用
一种长效血管紧张素转换酶抑制剂。
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險聲明
危險分類
Repr. 2
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
Marta de Diego et al.
Journal of chromatographic science, 52(10), 1193-1197 (2013-12-04)
A simple and rapid stability-indicating liquid chromatographic method was developed and validated for the simultaneous determination of lisinopril and hydrochlorotiazide (HCTZ) in drug substances and dosage forms in the presence of degradation products. Forced degradation studies were conducted on the
John J V McMurray et al.
The New England journal of medicine, 371(11), 993-1004 (2014-09-02)
We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. In this double-blind trial, we randomly assigned 8442 patients with class
[Heart failure and LCZ696].
Guy Sabourin
Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec, 12(1), 61-61 (2015-02-06)
Neprilysin inhibition--a novel therapy for heart failure.
Mariell Jessup
The New England journal of medicine, 371(11), 1062-1064 (2014-09-02)
PARADIGM-HF--the experts' discussion.
Mariell Jessup et al.
The New England journal of medicine, 371(11), e15-e15 (2014-09-04)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门